Target intelligence / Profile preview

RNA, U6 small nuclear 232, pseudogene (RNU6-232P)

Target: RNU6-232P
Molecular classification: Other (Processed pseudogene; does not fit enzyme, receptor, channel, transporter, transcription factor, or other therapeutic target families)

Overview

RNU6-232P is a human processed pseudogene derived from the U6 small nuclear RNA locus. U6 snRNA is an integral component of the spliceosome, involved in pre-mRNA splicing[1][3][6]. However, RNU6-232P itself is a nonfunctional genomic copy formed by retrotransposition of the active gene[5][7]. Unlike functional U6 snRNA, RNU6-232P does not contribute directly to cellular processes. Some pseudogenes can regulate gene expression by acting as regulatory RNA molecules or miRNA sponges, but no such function has been reported for RNU6-232P specifically[4][5]. There is also no evidence linking this pseudogene to human disease, biomarker status, or drug interactions. RNU6-232P is *not* a therapeutic target, but a nonfunctional genomic remnant (pseudogene) of U6 snRNA, with no proven biological or disease relevance to date[4][5][2][7].

Other names: RNU6-232PRNA, U6 small nuclear 232, pseudogene

Mechanism of action

None; pseudogenes are not conventional drug targets

Biological functions

None directly; as a processed pseudogene, no known biological function attributed to RNU6-232P specifically. Some pseudogenes may modulate transcription or act as competing endogenous RNAs (ceRNAs), but no such evidence is reported for RNU6-232P itself

Disease associations

None definitively reported for RNU6-232P. In general, certain pseudogenes may regulate parental gene expression or act as miRNA sponges, but no disease linkage is documented for this specific pseudogene

Safety considerations

Not applicable; processed pseudogenes do not produce proteins or active RNA with safety implications

Biomarkers

None established for clinical use

Beyond the preview

Go deeper on RNA, U6 small nuclear 232, pseudogene (RNU6-232P).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

Drug candidates
Developers
Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

Trial design
Status
Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

Programs
Modalities
Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

Publications
Sources
Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

Patents
Assignees
Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

Biology
Development news
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RNA, U6 small nuclear 232, pseudogene (RNU6-232P).

Explore the full profile